Human papillomavirus (HPV) vaccines: Prospects for eradicating cervical cancer

Journal of Family Planning and Reproductive Health Care

Volumn 30, Issue 4, 2004, Pages 213-215

  Stanley, Margaret A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

CANCER PREVENTION; CLINICAL TRIAL; DISEASE ASSOCIATION; EDITORIAL; HUMAN; IMMUNIZATION; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 7044262106     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/0000000042177162     Document Type: Editorial

References (5)

1. Schiffman M, Kjaer SK. Natural history of anogenital papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31: 14-19.
2. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.
3. Bosch FX, Sanjose S. Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3-11.
4. Brown DR, Ault KA, Wheeler CM, et al. A dose ranging study of the safety and immunogenicity profiles of a quadrivalent HPV (types 6, 11, 16 and 18) L1 VLP candidate vaccine in young healthy women. Abstract (0-51) presented at the 19th International Papillomavirus Workshop, Florianopolis, Brazil, 1-7 September 2001.
5. Stanley MA. Genital human papillomavirus infections - current and prospective therapies. J Natl Cancer Inst Monogr 2003; 31: 117-124.